meixatech
6 minutes ago
LT - I am not working for pharma, but I sure am aware of the neuorpharma literature. The literature is massive on ampakines reporting extraordinary preclinical findings on, as you know, multiple fronts. Big pharma must be aware of this literature. They are likely coming to RSPI, not the other way